Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 2:11:635823.
doi: 10.3389/fphar.2020.635823. eCollection 2020.

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis

Varvara Choida  1   2 , Margaret Hall-Craggs  3 , Bethany R Jebson  1   4 , Corinne Fisher  1   2 , Maria Leandro  1   2 , Lucy R Wedderburn  1   4   5 , Coziana Ciurtin  1   2
Affiliations
Review

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis

Varvara Choida et al. Front Pharmacol. .

Abstract

Background: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis of childhood, characterized by various clinical phenotypes associated with variable prognosis. Significant progress has been achieved with the use of biologic treatments, which specifically block pro-inflammatory molecules involved in the disease pathogenesis. The most commonly used biologics in JIA are monoclonal antibodies and recombinant proteins targeting interleukins 1 (IL-1) and 6 (IL-6), and tumor necrosis factor α (TNF-α). Several biomarkers have been investigated in JIA. Aims: To assess the level of evidence available regarding the role of biomarkers in JIA related to guiding clinical and therapeutic decisions, providing disease prognostic information, facilitating disease activity monitoring and assessing biologic treatment response in JIA, as well as propose new strategies for biologic therapy-related biomarker use in JIA. Methods: We searched PubMed for relevant literature using predefined key words corresponding to several categories of biomarkers to assess their role in predicting and assessing biologic treatment response and clinical remission in JIA. Results: We reviewed serological, cellular, genetic, transcriptomic and imaging biomarkers, to identify candidates that are both well-established and widely used, as well as newly investigated in JIA on biologic therapy. We evaluated their role in management of JIA as well as identified the unmet needs for new biomarker discovery and better clinical applications. Conclusion: Although there are no ideal biomarkers in JIA, we identified serological biomarkers with potential clinical utility. We propose strategies of combining biomarkers of response to biologics in JIA, as well as routine implementation of clinically acceptable imaging biomarkers for improved disease assessment performance.

Keywords: biologics; cellular biomarkers; imaging biomarkers; juvenile idiopathic arthritis; serological biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Potential predictive biomarkers of response to biologic treatment.
See this image and copyright information in PMC

References

    1. Alberdi-Saugstrup M., Nielsen S., Mathiessen P., Nielsen C. H., Müller K. (2017). Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clin. Rheumatol. 36, 67–75. 10.1007/s10067-016-3375-x - DOI - PubMed
    1. Alexeeva E. I., Namazova-Baranova L. S., Bzarova T. M., Valieva S. I., Denisova R. V., Sleptsova T. V., et al. (2017). Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr. Rheumatol. Online J. 15, 51 10.1186/s12969-017-0178-9 - DOI - PMC - PubMed
    1. Anink J., Van Suijlekom-Smit L. W. A., Otten M. H., Prince F. H. M., Van Rossum M. A. J., Dolman K. M., et al. (2015). MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res. Ther. 17, 200 10.1186/s13075-015-0723-1 - DOI - PMC - PubMed
    1. Aquilani A., Marafon D. P., Marasco E., Nicolai R., Messia V., Perfetti F., et al. (2018). Predictors of flare following etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J. Rheumatol. 45, 956–961. 10.3899/jrheum.170794 - DOI - PubMed
    1. Arthur V. L., Shuldiner E., Remmers E. F., Hinks A., Grom A. A., Foell D., et al. (2018). IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 70, 1319–1330. 10.1002/art.40498 - DOI - PMC - PubMed

LinkOut - more resources